Caxton Associates LP Xencor Inc Transaction History

Caxton Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$20.08 - $25.39 $562,701 - $711,503	28,023 New	28,023 $564,000
Q3 2022 Nov 14, 2022	SELL	$24.62 - $32.44 $66,867 - $88,107	-2,716 Reduced 11.86%	20,180 $524,000
Q2 2022 Aug 15, 2022	SELL	$19.74 - $29.01 $104,148 - $153,056	-5,276 Reduced 18.73%	22,896 $627,000
Q1 2022 May 16, 2022	BUY	$26.68 - $41.63 $751,628 - $1.17 Million	28,172 New	28,172 $752,000
Q3 2020 Nov 16, 2020	SELL	$30.09 - $43.02 $273,758 - $391,395	-9,098 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$27.76 - $33.42 $252,560 - $304,055	9,098 New	9,098 $295,000

214

71.8M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.09B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.